Results 131 to 140 of about 20,576 (195)

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration [PDF]

, 2016

core   +1 more source

Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion. [PDF]

BMC Ophthalmol
Cho J, Park SM, Kim CG, Kim JH.
europepmc   +1 more source

Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population. [PDF]

Ophthalmol Ther
Cheung CMG, Kikushima W, Teo KYC.
europepmc   +1 more source

Comparison of Short-term Outcomes Between Faricimab and High-Dose Aflibercept in Patients With Neovascular Age-related Macular Degeneration. [PDF]

J Vitreoretin Dis
Shiratori M, Maruyama-Inoue M, Yanagi Y, Inoue T, Kadonosono K.   +4 more
europepmc   +1 more source

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM.   +21 more
europepmc   +1 more source

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial. [PDF]

Neonatology
Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, Athanikar A, Vitti R, Chu K, Iveli P, Zhao F, Schlief S, Leal S, Niesen T, Brandau K, Miller T, Köfüncü E, Fielder AR.   +17 more
europepmc   +1 more source

Comparative evaluation of stability, efficacy, and sterility in five repackaged intravitreal anti-vascular endothelial growth factor medications. [PDF]

Sci Rep
Thunwiriya P, Phetruen T, Chaiwijit P, Tonawannakorn C, Dekham K, Thadtapong N, Chaturongakul S, Charoensawan V, Chanarat S, Pakotiprapha D, Hanutsaha P.   +10 more
europepmc   +1 more source

Transient vitreous opacity following combined intravitreal injection of pegcetacoplan and faricimab-svoa in patients with neovascular age-related macular degeneration and geographic atrophy. [PDF]

Am J Ophthalmol Case Rep
Zhang Y, Wei C, Stewart JM.
europepmc   +1 more source

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. [PDF]

BMJ Open Ophthalmol
Balser S, Capsius B, Hole R, Papp A, Preissinger N, Rozenknop A, Tiko T.   +6 more
europepmc   +1 more source